Trial Profile

A Phase 1, 3-Part, Open-label Study to Assess the Pharmacokinetic Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 Tablet Formulations, and the Food Effect on the Pharmacokinetics of BMS-986278 When Orally Administered as a Phase 3 Tablet Formulation in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Admilparant (Primary) ; Nintedanib
Indications Idiopathic pulmonary fibrosis; Liver disorders; Pulmonary fibrosis
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

14 Mar 2025 Status changed from recruiting to completed.
18 Dec 2024 Planned End Date changed from 22 Nov 2024 to 16 Feb 2025.
18 Dec 2024 Planned primary completion date changed from 22 Nov 2024 to 16 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com